Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TRAP1 | Q12931 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL500704 | 0.90 | APOBEC3A (0.43) | LMNATSHRSMN1; SMN2MAPTKDM4E | |
| SCHEMBL3993912 | 0.86 | TSHR (0.49) | LMNATSHRSMN1; SMN2HSP90AA1MAPT | |
| SCHEMBL6746692 | 0.84 | TSHR (0.47) | LMNATSHRSMN1; SMN2HSP90AA1MAPT | |
| SCHEMBL1866995 | 0.84 | PDK1 (0.42) | SMN1; SMN2HSP90AA1KDM4EALDH1A1TRAP1 | |
| SCHEMBL1864994 | 0.83 | HSP90AA1 (0.42) | TSHRHSP90AA1TRAP1HSP90B1PDK1 | |
| SCHEMBL1864619 | 0.82 | HSP90AA1 (0.44) | HSP90AA1HSD17B10MEN1KMT2AALOX15 | |
| SCHEMBL1861871 | 0.81 | PDK1 (0.41) | TSHRHSP90AA1TRAP1HSP90B1PDK1 | |
| SCHEMBL17060000 | 0.80 | HSP90AA1 (0.48) | LMNASMN1; SMN2HSP90AA1MAPTKDM4E | |
| SCHEMBL3998734 | 0.79 | NPSR1 (0.43) | LMNATSHRSMN1; SMN2HSP90AA1MAPT | |
| SCHEMBL6746914 | 0.79 | HSP90AA1 (0.47) | LMNATSHRSMN1; SMN2HSP90AA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150283147-A1 | TREATING POLYCYSTIC KIDNEY DISEASE WITH HSP90 INHIBITORY COMPOUNDS | THE INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2015-10-08 | — | — | US | disclosed |
| US-20150283147-A1 | TREATING POLYCYSTIC KIDNEY DISEASE WITH HSP90 INHIBITORY COMPOUNDS | THE INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2015-10-08 | — | — | US | disclosed |
| US-20150283147-A1 | TREATING POLYCYSTIC KIDNEY DISEASE WITH HSP90 INHIBITORY COMPOUNDS | THE INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2015-10-08 | — | — | US | disclosed |
| EP-2118077-B1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140288301-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288301-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288301-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-09-25 | — | — | US | disclosed |
| CN-101679319-B | Triazole compounds useful for the treatment of proliferative disorders such as cancer | SYNTA PHARMACEUTICALS CORP | 2014-07-09 | — | — | CN | disclosed |
| US-8748424-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748424-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130072489-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8299107-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299107-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299107-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110105483-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110105483-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110105483-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORPORATION | 2011-05-05 | — | — | US | disclosed |
| CN-101679319-A | Triazole compounds useful for the treatment of proliferative disorders such as cancer | SYNTA PHARMACEUTICALS CORP | 2010-03-24 | — | — | CN | disclosed |
| EP-2118077-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008097640-A2 | TRIAZOLE COMPOUNDS THAT ARE USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS, SUCH AS CANCER | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283147-A1 | TREATING POLYCYSTIC KIDNEY DISEASE WITH HSP90 INHIBITORY COMPOUNDS | HSP90B1, HSP90AB1, HSP90AA1 | LMNA 4105/4885TSHR 4157/4885SMN1; SMN2 4810/4885 |
| US-20110105483-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AA1, HSP90AB2P | LMNA 4608/4885TSHR 1442/4885SMN1; SMN2 4824/4885 |
| US-20140288301-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | LMNA 4005/4885TSHR 4046/4885SMN1; SMN2 4584/4885 |
| US-20130072489-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | LMNA 3854/4885TSHR 3737/4885SMN1; SMN2 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.